SIOUX FALLS, SD--(Marketwired - Dec 22, 2014) - Mitogenetics, a biomedical technology firm in partnership with the State University of New York, is developing technology to regulate the action of mitochondria. Through a series of breakthroughs in therapeutic strategies in human disease disorders, mitochondrial dysfunction has been linked to diseases such as diabetes Type II, obesity, hypertension, cardiovascular disease and neurodegenerative diseases such as Alzheimer's, Lou Gehrig's and Parkinson's.
Mitochondria are principally responsible for producing more than ninety-percent of a cell's energy, which is necessary to sustain life and support growth. Mitochondrial dysfunction is believed to cause certain attacks on a human body's organ, endocrine and respiratory systems -- parts of the body that require the most energy to function.
Mitogenetics, founded in 2010, is focused on the research, development and refinement of biomedical technology, in particular primordial energy control and signaling systems regulating mitochondrial metabolism. The goal is to control mitochondrial energy balance via natural processes and dietary compounds for medicinal remedies. The company is currently seeking fundraising to continue the research and licensing commercially viable products.
"Mitogenetics is a fairly new company and through our partnership with a well-established research facility such as the State University of New York at Old Westbury, we are looking to restore normal mitochondrial function in persons suffering from mitochondrial dysfunction," said Marcia Hendrickson, President and Chief Executive Officer, Mitogenetics. "We aim to find the cause of diseases affect a large number of people and also help preserve normal mitochondrial function in healthy persons effectively."
Additionally, the company was selected as one of the top 50 innovators at the 8th Annual New England Venture Summit where they were able to present their business platforms to a panel of potential investors and industry influencers.
For more information, visit http://mitogenetics.com/
About Mitogenetics
MitoGenetics was formed December 17, 2010 by Dr. William P. Switzer, DVM, PhD, Dr. h.c.. The Organization is operated by the Val-Add Corporation, a management corporation that in the last several years has assisted in the development of more than 20 ethanol plants in eight states, as well as working with projects as diverse as biodiesel production, soybean crushing, egg-laying, beef processing, fish farming, and dairy production. The company is under the guidance of Marcia Hendrickson, who serves as the CEO. Prior to MitoGenetics Hendrickson was the founding Executive Director of the Enterprise Institute which served as a virtual incubator for commercialization of research and growth oriented startup businesses. Many companies have been launched with her assistance including Didget a firm later acquired purchased by Bayer Diabetes Care is one such company.